Swedish Orphan Biovitrum AB (publ) banner

Company Overview

Business Description

Sector
Health Care
Industry
Biotechnology
Headquarters
Sweden SE
Employees
1 969
IPO date
Sep 15, 2006

Swedish Orphan Biovitrum, usually called Sobi, is a biopharmaceutical company that develops and sells medicines for rare diseases. Its main focus is on blood disorders, immune-related conditions, and other specialist therapies that treat patients with serious illnesses that are often hard to manage with standard drugs.

Sobi makes money by selling prescription medicines to hospitals, specialty pharmacies, and healthcare systems, often through long-term treatment relationships. Its products include therapies used in hemophilia and other rare blood diseases, as well as medicines for certain immune and inflammatory conditions. The company also works with partners to develop and commercialize some of its treatments, which can add licensing and collaboration income.

What makes Sobi different is its focus on a narrow set of rare diseases where patients need highly targeted, specialized care. Instead of selling a broad mix of mass-market drugs, it concentrates on treatments that are used by smaller patient groups but require deep medical expertise, strong relationships with specialists, and reliable supply.

Swedish Orphan Biovitrum AB (publ) Investor Relations

Address
Norra Stationsgatan 93A
Stockholm
Sweden

Business Segments

Hematology

This part of Sobi sells medicines for blood disorders, especially treatments for hemophilia and other conditions that affect how blood clots.

Customers and revenue model

Immunology

This part of Sobi provides medicines used to treat rare immune and inflammation-related diseases, including conditions where the body’s immune system attacks healthy tissue or causes severe inflammation.

Customers and revenue model

Specialty care

Description, customers and revenue model

Management

Dr. Guido Oelkers Ph.D.

CEO & President

Biography unavailable

Mr. Henrik Stenqvist

Chief Financial Officer

Biography unavailable

Mr. Torbjörn Hallberg

General Counsel & Head of Legal Affairs

Biography unavailable

Mr. Daniel Rankin

Head of Strategy & Corporate Development

Biography unavailable

Ms. Lena Bjurner

Head of Human Resources

Biography unavailable

Mr. Armin Reininger M.D., Ph.D.

Senior Scientific & Medical Advisor

Biography unavailable

Mr. Norbert Oppitz

Head of International

Biography unavailable

Mr. Sofiane Fahmy

Head of Europe

Biography unavailable

Mr. Duane H. Barnes

Head of North America

Biography unavailable

Mr. Mahmood Ladha

Head of Strategic Transformation Operations

Biography unavailable

1 / 10